MSB 5.24% $1.11 mesoblast limited

Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-133

  1. 11,047 Posts.
    lightbulb Created with Sketch. 692
    Gotta laugh as you are not being mindfull of a few things eg

    1) the very strong p value for pain releif at 12 months
    2) the alarming opioid abuse problem in the states leading to
    3) pressure to ''do something''
    4) the incoming head of the FDA has point 3 as a major focus
    5) the incoming head of the FDA wants to speed up approvals
    6) a halt due to overwhelming efficacy stats is likely quite early in the piece given the strong p values obtained previously.

    The p value will enable ''doing something'' quicker then normal time lines


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.11
Change
0.055(5.24%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.05 $1.13 $1.04 $6.781M 6.207M

Buyers (Bids)

No. Vol. Price($)
3 43856 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.11 66000 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.